SurmodicsSRDX
SRDX
0
Funds holding %
of 7,139 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
117% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 12
100% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]
95% more call options, than puts
Call options by funds: $1.33M | Put options by funds: $681K
8% more funds holding
Funds holding: 126 [Q3] → 136 (+10) [Q4]
8% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 40
2% more capital invested
Capital invested by funds: $459M [Q3] → $469M (+$10.1M) [Q4]
0.65% less ownership
Funds ownership: 83.47% [Q3] → 82.81% (-0.65%) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for SRDX.
Financial journalist opinion
Based on 8 articles about SRDX published over the past 30 days
Positive
Benzinga
2 weeks ago
Top 3 Health Care Stocks You'll Regret Missing This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Positive
Zacks Investment Research
2 weeks ago
SurModics (SRDX) Loses -13.87% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for SurModics (SRDX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Neutral
Business Wire
2 weeks ago
Surmodics Announces Successful Early Clinical Use of Pounce™ XL Thrombectomy System, Suitable for Non-Surgical Removal of Thrombi and Emboli from Iliac and Femoral Arteries
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the successful early clinical use of its Pounce™ XL Thrombectomy System. The Pounce XL Thrombectomy System received U.S. Food and Drug Administration (FDA) 510(k) clearance in September 2024, and is currently in limited market release (LMR), with full commercial launch planned following completion of the LMR.
Negative
Zacks Investment Research
3 weeks ago
Surmodics Stock Down Despite Q1 Earnings Beat, Gross Margin Up
Despite the strength in Pounce thrombectomy device platforms, SRDX's first-quarter fiscal 2025 top line is dampened by weak segmental revenues.
Positive
Zacks Investment Research
3 weeks ago
Compared to Estimates, SurModics (SRDX) Q1 Earnings: A Look at Key Metrics
The headline numbers for SurModics (SRDX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Negative
Zacks Investment Research
3 weeks ago
SurModics (SRDX) Reports Q1 Loss, Misses Revenue Estimates
SurModics (SRDX) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to break-even earnings per share a year ago.
Neutral
Business Wire
3 weeks ago
Surmodics Reports First Quarter of Fiscal Year 2025 Financial Results
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its first quarter ended December 31, 2024. First Quarter Fiscal 2025 Financial Summary Total Revenue of $29.9 million, a decrease of 2% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon (“DCB”) license fee revenue(1) of $28.7 million, a decrease of 3% year-over-year GAAP.
Positive
Zacks Investment Research
4 weeks ago
Here's Why You Should Add Surmodics Stock to Your Portfolio Now
SRDX stock falls more than 6% so far this year. However, this provides a unique opportunity to generate double-digit return within a couple of months.
Negative
Zacks Investment Research
1 month ago
After Plunging -10.42% in 4 Weeks, Here's Why the Trend Might Reverse for SurModics (SRDX)
SurModics (SRDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Positive
Zacks Investment Research
1 month ago
SurModics (SRDX) Upgraded to Strong Buy: What Does It Mean for the Stock?
SurModics (SRDX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Charts implemented using Lightweight Charts™